Skip to main content
Top
Published in: Supportive Care in Cancer 5/2017

Open Access 01-05-2017 | Review Article

Hypercalcaemia and hypocalcaemia: finding the balance

Authors: Jean-Jacques Body, Daniela Niepel, Giuseppe Tonini

Published in: Supportive Care in Cancer | Issue 5/2017

Login to get access

Abstract

Calcium metabolism in cancer and hypercalcaemia of malignancy

The balance between bone formation and resorption may be disrupted in patients with cancer, leading either to increased bone resorption, calcium release, and possibly hypercalcaemia, or to increased bone formation, sequestration of calcium, and possibly hypocalcaemia. In adults, hypercalcaemia of malignancy is most common in patients with tumours that produce factors that induce osteoclast activation and enhance bone resorption. Impaired renal function and increased renal tubular calcium resorption may further affect calcium levels.

Treatment of hypercalcaemia of malignancy

Inhibitors of bone resorption, first the bisphosphonates and, later, denosumab, have been shown to be effective in hypercalcaemia treatment. Bisphosphonates (which are administered intravenously) are approved for hypercalcaemia of malignancy and are the current mainstay of treatment, whereas denosumab (which is administered subcutaneously) may offer an option for patients who do not respond to bisphosphonates or suffer from renal insufficiency.

Hypocalcaemia: treatment and prevention

Hypocalcaemia is most common in patients with prostate cancer and osteoblastic bone metastases, but can occur in patients with a variety of tumour types who are receiving inhibitors of bone resorption. While patients often respond to calcium and vitamin D supplementation, prevention should be the aim; at-risk patients should be identified before starting treatment with inhibitors of bone resorption, be closely monitored during at least the first few months of treatment, and receive concomitant calcium and vitamin D supplementation unless hypercalcaemia is present.

Conclusion

Both hypercalcaemia and hypocalcaemia can be serious if left untreated. It is therefore important that patients with cancer are closely monitored and receive adequate prevention and treatment measures to maintain normal blood calcium levels.
Literature
1.
go back to reference Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-related cancer 12(3):549–583. doi:10.1677/erc.1.00543 CrossRefPubMed Clines GA, Guise TA (2005) Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocrine-related cancer 12(3):549–583. doi:10.​1677/​erc.​1.​00543 CrossRefPubMed
6.
go back to reference Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1(9):944–949CrossRefPubMed Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW (1995) Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1(9):944–949CrossRefPubMed
7.
go back to reference Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62(3):917–923PubMed Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62(3):917–923PubMed
9.
go back to reference Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C (2014) Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis 31(2):247–256. doi:10.1007/s10585-013-9625-2 CrossRefPubMed Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C (2014) Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment. Clin Exp Metastasis 31(2):247–256. doi:10.​1007/​s10585-013-9625-2 CrossRefPubMed
11.
go back to reference Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98(7):1544–1549. doi:10.1172/jci118947 CrossRefPubMedPubMedCentral Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, Yoneda T, Mundy GR (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98(7):1544–1549. doi:10.​1172/​jci118947 CrossRefPubMedPubMedCentral
12.
go back to reference Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 21(7):1045–1059. doi:10.1359/jbmr.060416 CrossRef Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 21(7):1045–1059. doi:10.​1359/​jbmr.​060416 CrossRef
13.
go back to reference Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51(11):3059–3061PubMed Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51(11):3059–3061PubMed
14.
go back to reference Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277(27):24571–24578. doi:10.1074/jbc.M202561200 CrossRefPubMed Kakonen SM, Selander KS, Chirgwin JM, Yin JJ, Burns S, Rankin WA, Grubbs BG, Dallas M, Cui Y, Guise TA (2002) Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 277(27):24571–24578. doi:10.​1074/​jbc.​M202561200 CrossRefPubMed
19.
go back to reference Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253(2):395–400. doi:10.1006/bbrc.1998.9788 CrossRefPubMed Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, Morinaga T, Higashio K (1998) RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253(2):395–400. doi:10.​1006/​bbrc.​1998.​9788 CrossRefPubMed
20.
go back to reference Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159–178CrossRefPubMed Chirgwin JM, Guise TA (2000) Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 10(2):159–178CrossRefPubMed
24.
go back to reference Yucel B, Celasun MG, Oztoprak B, Hasbek Z, Bahar S, Kacan T, Bahceci A, Seker MM (2015) The negative prognostic impact of bone metastasis with a tumor mass. Clinics (Sao Paulo, Brazil) 70(8):535–540. doi:10.6061/clinics/2015(08)01 CrossRef Yucel B, Celasun MG, Oztoprak B, Hasbek Z, Bahar S, Kacan T, Bahceci A, Seker MM (2015) The negative prognostic impact of bone metastasis with a tumor mass. Clinics (Sao Paulo, Brazil) 70(8):535–540. doi:10.​6061/​clinics/​2015(08)01 CrossRef
25.
go back to reference Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL (2013) Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28(2):333–340. doi:10.1002/jbmr.1749 CrossRef Morrissey C, Roudier MP, Dowell A, True LD, Ketchanji M, Welty C, Corey E, Lange PH, Higano CS, Vessella RL (2013) Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 28(2):333–340. doi:10.​1002/​jbmr.​1749 CrossRef
26.
go back to reference Yates AJ, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR (1988) Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest 81(3):932–938. doi:10.1172/jci113406 CrossRefPubMedPubMedCentral Yates AJ, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR (1988) Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents. J Clin Invest 81(3):932–938. doi:10.​1172/​jci113406 CrossRefPubMedPubMedCentral
27.
28.
go back to reference Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A (2009) Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 12(1):94–99. doi:10.1038/pcan.2008.10 CrossRefPubMed Tucci M, Mosca A, Lamanna G, Porpiglia F, Terzolo M, Vana F, Cracco C, Russo L, Gorzegno G, Tampellini M, Torta M, Reimondo G, Poggio M, Scarpa RM, Angeli A, Dogliotti L, Berruti A (2009) Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. Prostate Cancer Prostatic Dis 12(1):94–99. doi:10.​1038/​pcan.​2008.​10 CrossRefPubMed
29.
go back to reference Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European journal of cancer (Oxford, England : 1990) 51(13):1812–1821. doi:10.1016/j.ejca.2015.05.016 CrossRef Body JJ, Bone HG, de Boer RH, Stopeck A, Van Poznak C, Damiao R, Fizazi K, Henry DH, Ibrahim T, Lipton A, Saad F, Shore N, Takano T, Shaywitz AJ, Wang H, Bracco OL, Braun A, Kostenuik PJ (2015) Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European journal of cancer (Oxford, England : 1990) 51(13):1812–1821. doi:10.​1016/​j.​ejca.​2015.​05.​016 CrossRef
30.
go back to reference Lumachi F, Brunello A, Roma A, Basso U (2009) Cancer-induced hypercalcemia. Anticancer Res 29(5):1551–1555PubMed Lumachi F, Brunello A, Roma A, Basso U (2009) Cancer-induced hypercalcemia. Anticancer Res 29(5):1551–1555PubMed
31.
go back to reference Basso U, Maruzzo M, Roma A, Camozzi V, Luisetto G, Lumachi F (2011) Malignant hypercalcemia. Curr Med Chem 18(23):3462–3467CrossRefPubMed Basso U, Maruzzo M, Roma A, Camozzi V, Luisetto G, Lumachi F (2011) Malignant hypercalcemia. Curr Med Chem 18(23):3462–3467CrossRefPubMed
35.
go back to reference Soyfoo MS, Brenner K, Paesmans M, Body JJ (2013) Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 21(5):1415–1419. doi:10.1007/s00520-012-1683-5 CrossRef Soyfoo MS, Brenner K, Paesmans M, Body JJ (2013) Non-malignant causes of hypercalcemia in cancer patients: a frequent and neglected occurrence. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 21(5):1415–1419. doi:10.​1007/​s00520-012-1683-5 CrossRef
36.
go back to reference Major P (2002) The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7(6):481–491CrossRefPubMed Major P (2002) The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 7(6):481–491CrossRefPubMed
38.
go back to reference Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP Jr, Olson BR, TL W, Mitnick ME, Broadus AE, Stewart AF (1990) Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322(16):1106–1112. doi:10.1056/nejm199004193221603 CrossRefPubMed Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell RP Jr, Olson BR, TL W, Mitnick ME, Broadus AE, Stewart AF (1990) Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322(16):1106–1112. doi:10.​1056/​nejm199004193221​603 CrossRefPubMed
39.
go back to reference Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ (1991) Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73(6):1309–1315. doi:10.1210/jcem-73-6-1309 CrossRefPubMed Grill V, Ho P, Body JJ, Johanson N, Lee SC, Kukreja SC, Moseley JM, Martin TJ (1991) Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J Clin Endocrinol Metab 73(6):1309–1315. doi:10.​1210/​jcem-73-6-1309 CrossRefPubMed
40.
go back to reference Ralston SH, Fogelman I, Gardiner MD, Boyle IT (1984) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 288(6428):1405–1408CrossRef Ralston SH, Fogelman I, Gardiner MD, Boyle IT (1984) Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 288(6428):1405–1408CrossRef
41.
43.
go back to reference Li X, Bie Z, Zhang Z, Li Y, Hu X, Liu W, Zhang S, Cheng G, Ai B (2015) Clinical analysis of 64 patients with lung-cancer-associated hypercalcemia. J Cancer Res Ther 11(Suppl):C275–C279. doi:10.4103/0973-1482.170539 PubMed Li X, Bie Z, Zhang Z, Li Y, Hu X, Liu W, Zhang S, Cheng G, Ai B (2015) Clinical analysis of 64 patients with lung-cancer-associated hypercalcemia. J Cancer Res Ther 11(Suppl):C275–C279. doi:10.​4103/​0973-1482.​170539 PubMed
44.
go back to reference de Wit S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120(10):610–614CrossRefPubMed de Wit S, Cleton FJ (1994) Hypercalcemia in patients with breast cancer: a survival study. J Cancer Res Clin Oncol 120(10):610–614CrossRefPubMed
45.
go back to reference Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med 115(2):115–121CrossRefPubMed Truong NU, deB Edwardes MD, Papavasiliou V, Goltzman D, Kremer R (2003) Parathyroid hormone-related peptide and survival of patients with cancer and hypercalcemia. Am J Med 115(2):115–121CrossRefPubMed
47.
go back to reference Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. The Quarterly journal of medicine 50(200):473–481PubMed Hosking DJ, Cowley A, Bucknall CA (1981) Rehydration in the treatment of severe hypercalcaemia. The Quarterly journal of medicine 50(200):473–481PubMed
48.
go back to reference Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978CrossRefPubMed Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961–2978CrossRefPubMed
52.
go back to reference Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19(2):558–567CrossRef Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E, Seaman J (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19(2):558–567CrossRef
53.
go back to reference MI H, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144–3152. doi:10.1210/jc.2014-1001 CrossRef MI H, Glezerman IG, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Ying W, Braun A, Jain RK (2014) Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 99(9):3144–3152. doi:10.​1210/​jc.​2014-1001 CrossRef
54.
go back to reference Henrich D, Hoffmann M, Uppenkamp M, Bergner R (2006) Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 116(3):165–172. doi:10.1159/000094676 CrossRefPubMed Henrich D, Hoffmann M, Uppenkamp M, Bergner R (2006) Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: case reports. Acta Haematol 116(3):165–172. doi:10.​1159/​000094676 CrossRefPubMed
55.
go back to reference Body JJ, Diel IJ, Tripathy D, Bergstrom B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15(3):299–302. doi:10.1111/j.1365-2354.2005.00641.x CrossRef Body JJ, Diel IJ, Tripathy D, Bergstrom B (2006) Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care (Engl) 15(3):299–302. doi:10.​1111/​j.​1365-2354.​2005.​00641.​x CrossRef
56.
go back to reference Body JJ, Louviaux I, Dumon JC (2000) Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 8(5):398–404CrossRef Body JJ, Louviaux I, Dumon JC (2000) Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 8(5):398–404CrossRef
57.
go back to reference Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 24(2):182–195. doi:10.1359/jbmr.081112 CrossRef Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK (2009) Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 24(2):182–195. doi:10.​1359/​jbmr.​081112 CrossRef
62.
go back to reference von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y (2016) Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24(3):1327–1337. doi:10.1007/s00520-015-2908-1 CrossRef von Moos R, Body JJ, Egerdie B, Stopeck A, Brown J, Fallowfield L, Patrick DL, Cleeland C, Damyanov D, Palazzo FS, Marx G, Zhou Y, Braun A, Balakumaran A, Qian Y (2016) Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24(3):1327–1337. doi:10.​1007/​s00520-015-2908-1 CrossRef
64.
go back to reference Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090CrossRefPubMed Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090CrossRefPubMed
65.
go back to reference Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613–2621. doi:10.1002/cncr.20308 CrossRefPubMed Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non-small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613–2621. doi:10.​1002/​cncr.​20308 CrossRefPubMed
66.
go back to reference Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882CrossRefPubMed Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879–882CrossRefPubMed
68.
go back to reference Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England) 377(9768):813–822. doi:10.1016/s0140-6736(10)62344-6 CrossRef Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England) 377(9768):813–822. doi:10.​1016/​s0140-6736(10)62344-6 CrossRef
69.
go back to reference Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A (2015) The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. European journal of cancer (Oxford, England : 1990) 51(11):1467–1475. doi:10.1016/j.ejca.2015.04.017 CrossRef Diel IJ, Body JJ, Stopeck AT, Vadhan-Raj S, Spencer A, Steger G, von Moos R, Goldwasser F, Feng A, Braun A (2015) The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease. European journal of cancer (Oxford, England : 1990) 51(11):1467–1475. doi:10.​1016/​j.​ejca.​2015.​04.​017 CrossRef
70.
go back to reference Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(9):1125–1132. doi:10.1200/jco.2010.31.3304 CrossRef Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(9):1125–1132. doi:10.​1200/​jco.​2010.​31.​3304 CrossRef
71.
go back to reference Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(35):5132–5139. doi:10.1200/jco.2010.29.7101 CrossRef Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 28(35):5132–5139. doi:10.​1200/​jco.​2010.​29.​7101 CrossRef
72.
go back to reference Vaughn CB, Vaitkevicius VK (1974) The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 34(4):1268–1271CrossRefPubMed Vaughn CB, Vaitkevicius VK (1974) The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 34(4):1268–1271CrossRefPubMed
73.
go back to reference Szentirmai M, Constantinou C, Rainey JM, Loewenstein JE (1995) Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. The Western journal of medicine 163(6):577–578PubMedPubMedCentral Szentirmai M, Constantinou C, Rainey JM, Loewenstein JE (1995) Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. The Western journal of medicine 163(6):577–578PubMedPubMedCentral
74.
go back to reference Domschke C, Schuetz F (2014) Side effects of bone-targeted therapies in advanced breast cancer. Breast care (Basel, Switzerland) 9(5):332–336. doi:10.1159/000368844 Domschke C, Schuetz F (2014) Side effects of bone-targeted therapies in advanced breast cancer. Breast care (Basel, Switzerland) 9(5):332–336. doi:10.​1159/​000368844
75.
go back to reference Kukreja SC, Shanmugam A, Lad TE (1988) Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 43(6):340–345CrossRefPubMed Kukreja SC, Shanmugam A, Lad TE (1988) Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 43(6):340–345CrossRefPubMed
76.
go back to reference Blackley S, Anderson K, Berg J (2015) A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment. The journal of the Royal College of Physicians of Edinburgh 45(2):133–135. doi:10.4997/jrcpe.2015.209 CrossRefPubMed Blackley S, Anderson K, Berg J (2015) A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment. The journal of the Royal College of Physicians of Edinburgh 45(2):133–135. doi:10.​4997/​jrcpe.​2015.​209 CrossRefPubMed
77.
go back to reference Breen TL, Shane E (2004) Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(8):1531–1532. doi:10.1200/jco.2004.99.013 CrossRef Breen TL, Shane E (2004) Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22(8):1531–1532. doi:10.​1200/​jco.​2004.​99.​013 CrossRef
78.
go back to reference Pusulari BB, Akbar RA, Butt M, ul Haq SM (2008) Hypocalcemia with bony metastases in prostate cancer. Journal of Ayub Medical College, Abbottabad : JAMC 20(1):138–139PubMed Pusulari BB, Akbar RA, Butt M, ul Haq SM (2008) Hypocalcemia with bony metastases in prostate cancer. Journal of Ayub Medical College, Abbottabad : JAMC 20(1):138–139PubMed
79.
go back to reference Kreutle V, Blum C, Meier C, Past M, Muller B, Schutz P, Borm K (2014) Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature. Swiss Med Wkly 144:w13979. doi:10.4414/smw.2014.13979 PubMed Kreutle V, Blum C, Meier C, Past M, Muller B, Schutz P, Borm K (2014) Bisphosphonate induced hypocalcaemia – report of six cases and review of the literature. Swiss Med Wkly 144:w13979. doi:10.​4414/​smw.​2014.​13979 PubMed
80.
go back to reference Epperla N, Pathak R (2015) Hypocalcemia secondary to zoledronate therapy in a patient with low vitamin D level. WMJ : official publication of the State Medical Society of Wisconsin 114(4):163–166 quiz 167 Epperla N, Pathak R (2015) Hypocalcemia secondary to zoledronate therapy in a patient with low vitamin D level. WMJ : official publication of the State Medical Society of Wisconsin 114(4):163–166 quiz 167
82.
go back to reference Ho JW, Sundar S (2012) Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clinical genitourinary cancer 10(1):50–53. doi:10.1016/j.clgc.2011.11.004 CrossRefPubMed Ho JW, Sundar S (2012) Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clinical genitourinary cancer 10(1):50–53. doi:10.​1016/​j.​clgc.​2011.​11.​004 CrossRefPubMed
83.
go back to reference Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European journal of cancer (Oxford, England : 1990) 48(16):3082–3092. doi:10.1016/j.ejca.2012.08.002 CrossRef Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S (2012) Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European journal of cancer (Oxford, England : 1990) 48(16):3082–3092. doi:10.​1016/​j.​ejca.​2012.​08.​002 CrossRef
84.
go back to reference Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24:447–455. doi:10.1007/s00520-015-2904-5 CrossRef Stopeck AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y, Martin M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun A (2015) Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24:447–455. doi:10.​1007/​s00520-015-2904-5 CrossRef
85.
go back to reference Singh D, Khaira NS, Sekhon JS (2004) Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15(12):1848. doi:10.1093/annonc/mdh479 CrossRef Singh D, Khaira NS, Sekhon JS (2004) Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15(12):1848. doi:10.​1093/​annonc/​mdh479 CrossRef
87.
go back to reference Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS (2011) Vitamin D status in patients with stage IV colorectal cancer: findings from intergroup trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(12):1599–1606. doi:10.1200/JCO.2010.31.7255 CrossRef Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS (2011) Vitamin D status in patients with stage IV colorectal cancer: findings from intergroup trial N9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(12):1599–1606. doi:10.​1200/​JCO.​2010.​31.​7255 CrossRef
88.
go back to reference Diel IJ, Hecker D, Hesse T, Kluikel C, Nusch A, Rohrberg R, Kurbacher C, Rueckinger S, Schilling J, Schultz H (2015) X-TREME: interim analysis from a German open-label, observational non-interventional study for treatment persistence with denosumab in routine use in adults with bone metastases secondary to solid tumours. Presented at the European Cancer Congress, 25–29 September 2015, Vienna, Austria Diel IJ, Hecker D, Hesse T, Kluikel C, Nusch A, Rohrberg R, Kurbacher C, Rueckinger S, Schilling J, Schultz H (2015) X-TREME: interim analysis from a German open-label, observational non-interventional study for treatment persistence with denosumab in routine use in adults with bone metastases secondary to solid tumours. Presented at the European Cancer Congress, 25–29 September 2015, Vienna, Austria
91.
go back to reference Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.1056/NEJMoa067312 CrossRefPubMed Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. doi:10.​1056/​NEJMoa067312 CrossRefPubMed
Metadata
Title
Hypercalcaemia and hypocalcaemia: finding the balance
Authors
Jean-Jacques Body
Daniela Niepel
Giuseppe Tonini
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3543-1

Other articles of this Issue 5/2017

Supportive Care in Cancer 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine